Drug discovery startup ArrePath lands $20M+ in digital health funding
Drug discovery start-up StopPath announced on Thursday that it has raised $20 million in a seed funding round led by the Boehringer Ingelheim Venture Fund, Insight Partners and Innospark Ventures.
Other participants in the round include Viva BioInnovator, Arimed Capital, PTX Capital and Nor’easter Ventures. The company, which is focused on developing new types of anti-infective drugs for improved antimicrobial resistance, plans to use the investment to support its machine learning-based drug discovery platform.
ArrePath has also named Dr. Lloyd Payne as President and CEO. Payne most recently served as executive vice president, head of anti-infectives, at German drug discovery company Evotec.
“This funding is a strong vote of confidence, by a global investment syndicate, in our platform and its enormous potential in anti-infective drug discovery,” Payne said in a statement. “The funding will enable the advancement of our initial leads and the expansion of our discovery efforts, as well as the enhancement of our imaging platform and the application of machine learning in new drug discovery to address the critical global health challenges.
Rupa Healthwhich offers a platform where providers can order a variety of lab tests and receive the results, secured $20 million in Series A funding.
The round was led by Bessemer Ventures with participation from existing investors including First Round Capital, Lachy Groom, SV Angel, Floodgate, Hustle Fund, Operator Collective, the Chainsmokers, Jared Leto and Joe Montana.
In one post on company websiteCEO and co-founder Tara Viswanathan said the platform allows vendors to order traditional labs alongside other tests developed by independent companies, like microbiome scans, which can be harder to access.
CancerIQ announced that it raised $14 million in a Series B funding round led by Merck Global Health Innovation Fund and Amgen Ventures. Other participants include McKesson Ventures, OSF Ventures and HealthX Ventures.
The startup’s platform is integrated into an EHR and helps providers determine a patient’s cancer risk based on family history, genetics, health behaviors and other factors. It can also send patients through different care pathways based on results, such as screenings, vaccinations, and lifestyle changes.
CancerIQ scored $4.8 million in Series A funding in 2020.
“CancerIQ’s vision is to end cancer as we know it by eliminating health disparities and democratizing access to the latest advances in cancer early detection and prevention,” said the co-founder and CEO Feyi Olopade Ayodele in a statement.
“We started by making genetic testing more accessible and connecting patients to the right preventive services at the right time. This latest round of funding will help CancerIQ reach more patients and connect with more innovations that promise to transform cancer from a deadly disease to a manageable disease. state.”
The round was led by Lightspeed Venture Partners, with participation from Maven Ventures and individual investors. The round comes about a year after the company announced a $1.8 million seed round.
Daybreak plans to use the funding to expand across the country and focus on health equity.
Julyan AI-enabled app that tracks metrics such as activity, sleep, lab results, EHR data and weather to help users manage chronic disease, raised $3.8 million in seed funding.
The round was led by Speedinvest and Norrsken VC, with participation from SoftBank’s Vision Fund Emerge program and Dieter von Holtzbrinck Ventures.
“Juli helps patients, providers and employers identify behavioral triggers that worsen or improve the most difficult to treat and complex chronic conditions, including asthma, migraines, depression and bipolar disorder,” said said CEO and co-founder Bettina Hein in a statement. “With the support of Speedinvest, Norrsken and our other investors, we will be able to expand our reach to improve patient health and reduce healthcare costs.”